<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27849307</article-id><article-id pub-id-type="pmc">5094419</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20160059</article-id><article-categories><subj-group subj-group-type="heading"><subject>Special Article</subject></subj-group></article-categories><title-group><article-title>Cardiopulmonary Bypass Ischemic Hepatitis Reported in Five
Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Damasceno</surname><given-names>Telma A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Scorzoni</surname><given-names>Adilson</given-names><suffix>Filho</suffix></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chahud</surname><given-names>Fernando</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rodrigues</surname><given-names>Alfredo Jos&#x000e9;</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vicente</surname><given-names>Walter Vilella de Andrade</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Evora</surname><given-names>Paulo Roberto Barbosa</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib></contrib-group><aff id="aff1"><label>1</label> Division of Cardiovascular and Thoracic Surgery, Department of
Surgery and Anatomy, Faculdade de Medicina de Ribeir&#x000e3;o Preto da Universidade
de S&#x000e3;o Paulo (FMRP-USP), SP, Brazil. </aff><author-notes><corresp id="c1"><bold>Correspondence Address:</bold> Paulo Roberto Barbosa Evora,
Faculdade de Medicina de Ribeir&#x000e3;o Preto da Universidade de S&#x000e3;o
Paulo, Department of Surgery and Anatomy, Av. Bandeirantes, 3900,
Ribeir&#x000e3;o Preto, SP, Brazil &#x02013; ZIP code: 14048-900, E-mail:
<email>prbevora@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Sep</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Sep</season><year>2016</year></pub-date><volume>31</volume><issue>4</issue><fpage>330</fpage><lpage>333</lpage><history><date date-type="received"><day>5</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>8</day><month>6</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>In cardiac surgery, the lung, renal and neurological events are the most
frequent complications. Less common, acute liver failure is a serious
complication that adds high morbidity, mortality, and costs. Therefore, this
communication aimed to retrospectively evaluate five patients who presented,
in 2014, severe acute liver failure in the immediate postoperative
period.</p></sec><sec><title>Methods</title><p>Retrospective data analysis of patients' medical records that showed severe
liver failure has been computed in the medical records of five patients
undergoing cardiac surgery at the Hospital da Faculdade de Medicina de
Ribeir&#x000e3;o Preto &#x02013; USP in the immediate postoperative period from
February 1, 2014 to December 12, 2014. The study selected five males
patients, 60 to 67 years old, cardiopulmonary bypass mean time of 101.4
minutes (varying from 80 to 140 minutes), who presented acute perioperative
liver failure.</p></sec><sec><title>Results</title><p>The five patients showed an impressive increase of blood transaminase (serum
alanine aminotransferase), suggesting acute hepatitis. The evolution of all
patients was catastrophic, with severe hemodynamic effects and death. Many
studies suggest that systemic hypotension is an important pathogenic factor
for ischemic hepatitis. However, our data and previous studies raise the
possibility that other yet unknown factors other than hypotension may be
part of the pathophysiology of cardiopulmonary bypass after ischemic
hepatitis (anticoagulation inadequate for the quality of heparin and
protamine, etc.).</p></sec><sec><title>Conclusion</title><p>Currently, there are no conclusive studies on the prevention of perioperative
liver failure. More well-designed studies are needed on the introduction and
evolution of liver dysfunction after cardiac surgery.</p></sec></abstract><kwd-group><kwd>Cardiopulmonary Bypass</kwd><kwd>Liver Failure</kwd><kwd>Hepatitis</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CI</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;= Cardiac index</td></tr><tr><td align="left" rowspan="1" colspan="1">CPB</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;= Cardiopulmonar
bypass</td></tr><tr><td align="left" rowspan="1" colspan="1">CVP</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;= Central venous
pressure</td></tr><tr><td align="left" rowspan="1" colspan="1">LDH</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;= Lactate
dehydrogenase</td></tr><tr><td align="left" rowspan="1" colspan="1">LFTs</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;= Liver function tests</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;= New York Heart
Association</td></tr><tr><td align="left" rowspan="1" colspan="1">SIELI</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;= Severe ischemic early
liver injury</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Cardiopulmonary bypass (CPB) is closely related to the progress of cardiac surgery in
complexity. However, it is well known that the postoperative complications are
directly related to the preoperative patients comorbidities and prolonged CPB time.
The most common ones are lung, kidney, and neurological complications. The less
common one, acute liver failure, is a serious complication that adds high morbidity,
mortality, and costs<sup>[<xref rid="B1" ref-type="bibr">1</xref>]</sup>. Instead
ischemic hepatitis, some authors prefer to use an unspecific nomenclature suggesting
and adopting severe ischemic early (first 48 hours) liver injury (SIELI) after
cardiac surgery is considered a rare postoperative complication with a limited
mention in the literature<sup>[<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>]</sup>. As ischemic hepatitis is
considered of low incidence, the study rationale included the intriguing observation
of five cases in a short time interval (ten months). Therefore, the aim of this
investigation was to identify patients with liver failure, classified as ischemic
hepatitis, in the immediate postoperative period when undergoing cardiac
surgery.</p></sec><sec><title>PATIENTS</title><p>The Institutional Ethics Committee waived the need for informed consent for this
anonymous retrospective chart analysis. The study included a cohort of five males
patients, with ages ranging 60-67 years, with CPB time varying from 80 to 140
minutes (mean time of 101.4 minutes) (<xref ref-type="table" rid="t1">Table
1</xref>), who showed acute liver failure after CPB. For the purpose of this study,
SIELI was defined as an acute increase in serum alanine aminotransferase levels to
more than 500 IU/L within 48 hours of surgery. In all patients, induction and
maintenance of anesthesia were performed according to the standard protocol, using
midazolam, sufentanil, and vecuronium. Only one patient received inhaled
sevoflurane, and other drugs are presented in <xref ref-type="table" rid="t2">Table
2</xref>. CPB was maintained according to an alpha-stat protocol. In blood gas
management, the arterial pH was maintained at 7.4, and the arterial PCO<sub>2</sub>
was regulated from 35 to 40 mmHg. Total CPB mean flow was 3.77 L/min/m<sup>2</sup>
(0.8 to 5.7 L/min/m<sup>2</sup>) and mean arterial pressure during bypass was kept
at greater than 70 mmHg with the use of norepinephrine if necessary. Minimal core
body temperature was 33&#x000b0;C.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and surgery data.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">Age</th><th align="center" rowspan="1" colspan="1">Gender</th><th align="center" rowspan="1" colspan="1">Ejection Fraction</th><th align="center" rowspan="1" colspan="1">Surgery Date</th><th align="center" rowspan="1" colspan="1">Surgery</th><th align="center" rowspan="1" colspan="1">CPB time (min)</th><th align="center" rowspan="1" colspan="1">Anoxia time (min)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">JTR</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">62%</td><td align="center" rowspan="1" colspan="1">12/17/2014</td><td align="center" rowspan="1" colspan="1">CABG</td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1">87</td></tr><tr><td align="center" rowspan="1" colspan="1">JJG</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">23%</td><td align="center" rowspan="1" colspan="1">06/24/2014</td><td align="center" rowspan="1" colspan="1">CABG</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">49</td></tr><tr><td align="center" rowspan="1" colspan="1">SSR</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">45%</td><td align="center" rowspan="1" colspan="1">07/17/2014</td><td align="center" rowspan="1" colspan="1">MiVP</td><td align="center" rowspan="1" colspan="1">140</td><td align="center" rowspan="1" colspan="1">101</td></tr><tr><td align="center" rowspan="1" colspan="1">AGN</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">50%</td><td align="center" rowspan="1" colspan="1">02/13/2014</td><td align="center" rowspan="1" colspan="1">AoVP</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">65</td></tr><tr><td align="center" rowspan="1" colspan="1">AAB</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">33%</td><td align="center" rowspan="1" colspan="1">07/15/2014</td><td align="center" rowspan="1" colspan="1">AoVP</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">60</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>CPB=cardiopulmonary bypass; CABG=coronary artery bypass graft;
MiVP=mitral valve prosthesis; AoVP=aortic valve prosthesis</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Intraoperative drugs.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="5" rowspan="1">Name</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Drug (mg)</td><td align="center" rowspan="1" colspan="1">AGN</td><td align="center" rowspan="1" colspan="1">AAB</td><td align="center" rowspan="1" colspan="1">JJG</td><td align="center" rowspan="1" colspan="1">JTR</td><td align="center" rowspan="1" colspan="1">SS</td></tr><tr><td align="left" rowspan="1" colspan="1">Midazolam</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Sulfentanil</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">220</td><td align="center" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1">Morfina</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Etomidate</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">Vecuronium</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">Ketamine</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Cefazolyn</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Vancomycin</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">1000</td><td align="center" rowspan="1" colspan="1">1000</td><td align="center" rowspan="1" colspan="1">1000</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Amicacyn</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><p>All five patients presented an impressive increase of blood transaminase,
respectively: 1022; 2027; 3624; 7359 and 2583 U (3383&#x000b1;2444.5 U), suggesting
acute hepatitis. A post-mortem histological examination revealed centrilobular liver
necrosis that is commonly misdiagnosed as ischemic hepatitis (<xref ref-type="fig" rid="f1">Figure 1</xref>). Survival time in Intensive Care Unit was on average
5.4 days after surgery, ranging from 2 to 13 days. The evolution of all patients was
catastrophic, with severe hemodynamic effects, multiple organ failures, and death
(<xref ref-type="table" rid="t3">Table 3</xref>).</p><p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>A &#x02013; several hepatocellular foci of necrosis (arrows) and steatosis
predominantly surrounding centrolobular veins; B &#x02013; details of
hepatocellular necrosis and steatosis (arrows) with many anucleated
hepatocytes presenting eosinophilic, degenerating cytoplasms; C &#x02013;
interface between viable hepatocytes (on the left) and necrotic cells
(on the right). The anucleated necrotic hepatocytes show contracted
cytoplasms (arrows); D &#x02013; interface between viable hepatocytesa (on the
right) and necrotic cells (on the left). The anucleated necrotic
hepatocytes show contracted cytoplasms (arrows).</p></caption><graphic xlink:href="rbccv-31-04-0330-g01"/></fig></p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Clinical laboratory data.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" rowspan="1">Aspartate Transaminase (AST)</th><th align="center" colspan="2" rowspan="1">Glucose</th><th align="center" rowspan="1" colspan="1">Amylase</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Name</td><td align="center" rowspan="1" colspan="1">Pre</td><td align="center" rowspan="1" colspan="1">Post</td><td align="center" rowspan="1" colspan="1">Pre</td><td align="center" rowspan="1" colspan="1">Post</td><td align="center" rowspan="1" colspan="1">Post</td></tr><tr><td align="left" rowspan="1" colspan="1">JTR</td><td align="center" rowspan="1" colspan="1">54.3</td><td align="center" rowspan="1" colspan="1">4119 (13<sup>rd</sup> day)</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">-327</td><td align="center" rowspan="1" colspan="1">509 (1<sup>st</sup> day)</td></tr><tr><td align="left" rowspan="1" colspan="1">JJG</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">4277.8 (2<sup>nd</sup> day)</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">291</td><td align="center" rowspan="1" colspan="1">132 (2<sup>nd</sup> day)</td></tr><tr><td align="left" rowspan="1" colspan="1">SSR</td><td align="center" rowspan="1" colspan="1">25.3</td><td align="center" rowspan="1" colspan="1">1022.3 (3<sup>rd</sup> day)</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">194</td><td align="center" rowspan="1" colspan="1">458 (1<sup>st</sup> day)</td></tr><tr><td align="left" rowspan="1" colspan="1">AGN</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">2027.6 (1<sup>st</sup> day)</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">&#x0003e;249</td><td align="center" rowspan="1" colspan="1">&#x000a0;-</td></tr><tr><td align="left" rowspan="1" colspan="1">AAB</td><td align="center" rowspan="1" colspan="1">14.2</td><td align="center" rowspan="1" colspan="1">2583.4 (4<sup>rh</sup> day)</td><td align="center" rowspan="1" colspan="1">&#x0003c;69</td><td align="center" rowspan="1" colspan="1">&#x0003e;302</td><td align="center" rowspan="1" colspan="1">1017 (1<sup>st</sup> day)</td></tr></tbody></table></table-wrap><sec sec-type="discussion"><title>DISCUSSION</title><p>The hepatic integrity is affected during cardiac surgery in particular when CPB
is adopted<sup>[<xref rid="B4" ref-type="bibr">4</xref>-<xref rid="B7" ref-type="bibr">7</xref>]</sup>. The recent review performed by Di Tomaso et
al.<sup>[<xref rid="B8" ref-type="bibr">8</xref>]</sup> summarized the
primary data about the severe liver dysfunction after CPB that can occur in
high-risk patients with a reduced physiological reserve. Pre-operative risk
factors are right-side heart failure, moderate-to-severe tricuspid
regurgitation, pulmonary hypertension (systolic pulmonary pressure above 45
mmHg), high preload [central venous pressure (CVP) above 8 mmHg] chronic heart
failure, New York Heart Association (NYHA) class II-IV and low ejection
fraction<sup>[<xref rid="B8" ref-type="bibr">8</xref>]</sup> are at a
higher risk to develop liver dysfunction after CPB. Interestingly, as reported
by Van Deursen et al.<sup>[<xref rid="B9" ref-type="bibr">9</xref>]</sup>, in
323 patients with heart failure, the hemodynamic profile can affect the liver
function tests (LFTs). In fact, elevated LFTs mainly indicate a higher CVP,
whereas only the presence of elevated aspartate aminotransferase, alanine
aminotransferase or direct bilirubinemia may indicate a low cardiac index
(CI)<sup>[<xref rid="B9" ref-type="bibr">9</xref>]</sup>.</p><p>Ischemic hepatitis can be found after a period of relatively profound hypotension
and hemodynamic instability, and it is often associated with left ventricular
dysfunction. The reduction in the hepatic blood flow leads to a consequent
hypoxia/anoxia of hepatocytes histologically characterized by the centrilobular
necrosis of zone 3 hepatocytes. Biochemical markers of ischemic hepatitis are an
increase in serum aspartate transaminase and serum alanine transaminase ALT
10-20 times the standard value, a rise of lactate dehydrogenase (LDH), total
bilirubin and a deficiency of hepatic coagulation factors with a consequent
prolongation of prothrombin time, 1-3 days after the CPB injury. Usually, these
biochemical indices return to normal within 5-10 days. If the hepatic biomarkers
remain persistently high, and other organs are affected from the perioperative
systemic hypoperfusion, multiorgan failure can occur, and it leads to death in
the majority of cases.</p><p>Eipel et al.<sup>[<xref rid="B10" ref-type="bibr">10</xref>]</sup> emphasize the
well-known physiological concept that among parenchymal organs, blood flow to
the liver is unique due to the dual supply from the portal vein and the hepatic
artery. Knowledge of the mutual communication of both the hepatic artery and the
portal vein is essential to understand hepatic physiology and pathophysiology.
To distinguish the particular importance of each of these inflows in normal and
abnormal states is still a challenging task and the subject of ongoing research.
A central mechanism that controls and allows constancy of hepatic blood flow is
the hepatic arterial buffer response. This buffer response is, surely, affected
by the artificial CPB hemodynamics allowing the controversial hypothesis that
the hepatic stasis should be more deleterious than the ischemia-reperfusion
injury.</p><p>Many studies suggest that systemic hypotension is an important pathogenic factor
for ischemic hepatitis. However, our data and previous studies raise the
possibility that other as yet unknown factors other than hypotension may be part
of the pathophysiology of CPB after ischemic hepatitis. Reinforcing this
hypothesis, it is important to note that the occurrence of the cases occurred in
a short time (some pathogen inoculation? Anesthesia drugs? Inadequate
anticoagulation due to the quality of heparin and protamine, etc). Sufentanil
was used in all patients, but the pharmacokinetics of phenylpiperidine opioids
such as fentanyl, sufentanil, and remifentanil appear to be unaffected by
hepatic disease<sup>[<xref rid="B11" ref-type="bibr">11</xref>]</sup>.</p><p>Halogenated inhalational anesthetics are associated with liver injury. Halothane,
enflurane, isoflurane, and desflurane are metabolized through the metabolic
pathway involving cytochrome P-450 2E1 (CYP2E1) and produce trifluoroacetate
components; some of which may be immunogenic. The severity of hepatotoxicity is
associated with the degree by which they undergo hepatic metabolism by this
cytochrome. However, liver toxicity is highly unlikely from sevoflurane as is
not metabolized to trifluoroacetyl compounds. Only one patient received
inhalational sevoflurane. Although anesthesia-induced hepatitis is not a common
occurrence, we must consider the association between this disorder and the use
of halogenated anesthetics<sup>[<xref rid="B12" ref-type="bibr">12</xref>]</sup>.</p><p>Hepatotoxic complications of long-term oral amiodarone therapy have been well
described; however, liver injury secondary to a parenteral infusion of
amiodarone is uncommon, potentially fatal, and poorly understood. The
hepatotoxicity is thought to result from the diluent polysorbate 80 and not the
amiodarone itself. Theories suggest an allergic or immunologic response leading
to alterations in the hepatocellular membrane while some propose that ischemia,
not a drug reaction, is true to blame. The patients under mitral valve surgery
used chronically preoperative amiodarone, which can induce severe acute
hepatitis. However, there is sufficient evidence to support amiodarone-induced
acute hepatotoxicity as a unique entity separate from ischemic
hepatitis<sup>[<xref rid="B13" ref-type="bibr">13</xref>]</sup>.</p><p>Currently, there are no conclusive studies on the prevention of perioperative
liver failure. More well-designed studies on the presentation and evolution of
liver dysfunction after cardiac surgery are needed. However, on the balance of
probability, based on wide literature search, it is more likely that this
hepatic failure is related to some intraoperative event rather than to drugs
including the volatile anesthetics. The possible connection among the hepatic
failure herein described and the drugs administered during this patient's
anesthesia, and CPB should be merely coincidental. Also, based on literature
data, the systemic hypotension or shock alone did not lead to ischemic hepatitis
in any patient. However, the great majority of patients with ischemic hepatitis
had passive liver congestion, suggesting that right-sided heart failure, with
resultant hepatic venous congestion, may predispose the liver to hepatic injury
induced by a hypotensive event.</p></sec><sec><title>Study Limitation</title><p>The article category limits the text in 1500 words. For this reason, we opted for
a more detailed data presentation as tables to better characterization of the
patients. Some of these results are not displayed as text, or even discussed,
and the reader should report a careful observation of the contents from
tables.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors&#x02019; roles &#x00026;
responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">TAD</td><td align="left" rowspan="1" colspan="1">Conception and design study; analysis and/or data
interpretation; manuscript writing or critical review of its
content; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ASF</td><td align="left" rowspan="1" colspan="1">Realization of operations and/or trials; final
manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FC</td><td align="left" rowspan="1" colspan="1">Analysis and/or data interpretation; final
manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AJR</td><td align="left" rowspan="1" colspan="1">Realization of operations and/or trials; final
manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WVAV</td><td align="left" rowspan="1" colspan="1">Final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRBE</td><td align="left" rowspan="1" colspan="1">Conception and design study; analysis and/or data
interpretation; manuscript writing or critical review of its
content; final manuscript approval</td></tr></tbody></table></table-wrap></sec></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the Division of Cardiovascular and Thoracic
Surgery, Department of Surgery and Anatomy, Faculdade de Medicina de
Ribeir&#x000e3;o Preto , Universidade de S&#x000e3;o Paulo, SP, Brazil.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hessel 2nd</surname><given-names>EA</given-names></name></person-group><article-title>Abdominal organ injury after cardiac surgery</article-title><source>Semin Cardiothorac Vasc Anesth</source><year>2004</year><volume>8</volume><issue>3</issue><fpage>243</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">15375483</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalopoulos</surname><given-names>A</given-names></name><name><surname>Alivizatos</surname><given-names>P</given-names></name><name><surname>Geroulanos</surname><given-names>S</given-names></name></person-group><article-title>Hepatic dysfunction following cardiac surgery determinants and
consequences</article-title><source>Hepatogastroenterology</source><year>1997</year><volume>44</volume><issue>15</issue><fpage>779</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">9222689</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raman</surname><given-names>JS</given-names></name><name><surname>Kochi</surname><given-names>K</given-names></name><name><surname>Morimatsu</surname><given-names>H</given-names></name><name><surname>Buxton</surname><given-names>B</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name></person-group><article-title>Severe ischemic early liver injury after cardiac
surgery</article-title><source>Ann Thorac Surg</source><year>2002</year><volume>74</volume><issue>5</issue><fpage>1601</fpage><lpage>1606</lpage><pub-id pub-id-type="pmid">12440615</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascione</surname><given-names>R</given-names></name><name><surname>Talpahewa</surname><given-names>S</given-names></name><name><surname>Rajakaruna</surname><given-names>C</given-names></name><name><surname>Reeves</surname><given-names>BC</given-names></name><name><surname>Lovell</surname><given-names>AT</given-names></name><name><surname>Cohen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Splanchnic organ injury during coronary surgery with or without
cardiopulmonary bypass a randomized, controlled trial</article-title><source>Ann Thorac Surg</source><year>2006</year><volume>81</volume><issue>1</issue><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">16368344</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raja</surname><given-names>SG</given-names></name><name><surname>Haider</surname><given-names>Z</given-names></name><name><surname>Ahmad</surname><given-names>M</given-names></name></person-group><article-title>Predictors of gastrointestinal complications after conventional
and beating heart coronary surgery</article-title><source>Surgeon</source><year>2003</year><volume>1</volume><issue>4</issue><fpage>221</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">15570766</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Ochiai</surname><given-names>R</given-names></name><name><surname>Takeda</surname><given-names>J</given-names></name><name><surname>Kikuchi</surname><given-names>H</given-names></name><name><surname>Ishibashi</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name></person-group><article-title>Off-pump coronary artery bypass attenuates transient
hepatocellular damage after myocardial revascularization</article-title><source>J Cardiothorac Vasc Anesth</source><year>2005</year><volume>19</volume><issue>5</issue><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">16202893</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahbazi</surname><given-names>S</given-names></name><name><surname>Panah</surname><given-names>A</given-names></name><name><surname>Sahmeddini</surname><given-names>MA</given-names></name></person-group><article-title>Evaluation of factors influencing liver function test in on-pump
coronary artery bypass graft surgery</article-title><source>Iran J Med Sci</source><year>2013</year><volume>38</volume><issue>4</issue><fpage>308</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">24293784</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Tomasso</surname><given-names>N</given-names></name><name><surname>Monaco</surname><given-names>F</given-names></name><name><surname>Landoni</surname><given-names>G</given-names></name></person-group><article-title>Hepatic and renal effects of cardiopulmonary
bypass</article-title><source>Best Pract Res Clin Anaesthesiol</source><year>2015</year><volume>29</volume><issue>2</issue><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">26060027</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Deursen</surname><given-names>VM</given-names></name><name><surname>Damman</surname><given-names>K</given-names></name><name><surname>Hillege</surname><given-names>HL</given-names></name><name><surname>van Beek</surname><given-names>AP</given-names></name><name><surname>van Veldhuisen</surname><given-names>DJ</given-names></name><name><surname>Voors</surname><given-names>AA</given-names></name></person-group><article-title>Abnormal liver function in relation to hemodynamic profile in
heart failure patients</article-title><source>J Card Fail</source><year>2010</year><volume>16</volume><issue>1</issue><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">20123323</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eipel</surname><given-names>C</given-names></name><name><surname>Abshagen</surname><given-names>K</given-names></name><name><surname>Vollmar</surname><given-names>B</given-names></name></person-group><article-title>Regulation of hepatic blood flow the hepatic arterial buffer
response revisited</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><issue>48</issue><fpage>6046</fpage><lpage>6057</lpage><pub-id pub-id-type="pmid">21182219</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosilkovska</surname><given-names>M</given-names></name><name><surname>Walder</surname><given-names>B</given-names></name><name><surname>Besson</surname><given-names>M</given-names></name><name><surname>Daali</surname><given-names>Y</given-names></name><name><surname>Desmeules</surname><given-names>J</given-names></name></person-group><article-title>Analgesics in patients with hepatic impairment pharmacology and
clinical implications</article-title><source>Drugs</source><year>2012</year><volume>72</volume><issue>12</issue><fpage>1645</fpage><lpage>1669</lpage><pub-id pub-id-type="pmid">22867045</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safari</surname><given-names>S</given-names></name><name><surname>Motavaf</surname><given-names>M</given-names></name><name><surname>Seyed Siamdoust</surname><given-names>SA</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name></person-group><article-title>Hepatotoxicity of halogenated inhalational
anesthetics</article-title><source>Iran Red Crescent Med J</source><year>2014</year><volume>16</volume><issue>9</issue><elocation-id/></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname><given-names>A</given-names></name><name><surname>Fenderson</surname><given-names>J</given-names></name><name><surname>Kenny</surname><given-names>P</given-names></name><name><surname>Helman</surname><given-names>DL</given-names></name></person-group><article-title>Severe acute hepatitis following intravenous amiodarone a case
report and review of the literature</article-title><source>Acta Gastroenterol Belg</source><year>2015</year><volume>78</volume><issue>2</issue><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">26151694</pub-id></element-citation></ref></ref-list></back></article>